Prednisolone tebutate
Blephamide, Cetapred, Chloroptic-p, Hydeltra-tba, Metimyd, Neo-delta-cortef, Neo-hydeltrasol, Pred, Prednisolone, Prelone, Sulphrin, Vasocidin (prednisolone tebutate) is a small molecule pharmaceutical. Prednisolone tebutate was first approved as Chloroptic-p s.o.p. on 1982-01-01. It is used to treat adrenal insufficiency, ankylosing spondylitis, asthma, atopic dermatitis, and berylliosis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 7 more
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Prednisolone tebutate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HYDELTRA-TBA | Merck & Co | N-010562 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| blephamide | New Drug Application | 2013-11-15 |
| econopred | 2006-09-11 | |
| orapred | New Drug Application | 2025-06-03 |
Indications
FDA
EMA
Show 19 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Prednisolone Acetate, Flo-Pred, Taro | |||
| 7799331 | 2028-10-11 | DP | U-139, U-1068 |
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AC: Corticosteroids for local oral treatment
— A01AC04: Prednisolone
— A01AC54: Prednisolone, combinations
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07E: Intestinal antiinflammatory agents
— A07EA: Corticosteroids acting locally
— A07EA01: Prednisolone
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AA: Corticosteroids, topical for treatment of hemorrhoids and anal fissures
— C05AA04: Prednisolone
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AA: Corticosteroids, weak (group i)
— D07AA03: Prednisolone
— D07B: Corticosteroids, combinations with antiseptics
— D07BA: Corticosteroids, weak, combinations with antiseptics
— D07BA01: Prednisolone and antiseptics
— D07C: Corticosteroids, combinations with antibiotics
— D07CA: Corticosteroids, weak, combinations with antibiotics
— D07CA03: Prednisolone and antibiotics
— D07X: Corticosteroids, other combinations
— D07XA: Corticosteroids, weak, other combinations
— D07XA02: Prednisolone
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB06: Prednisolone
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AD: Corticosteroid nasal preparations for topical use
— R01AD02: Prednisolone
— R01AD52: Prednisolone, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BA: Corticosteroid ophthalmologic antiinflammatory agents, plain
— S01BA04: Prednisolone
— S01BB: Corticosteroids and mydriatics in combination
— S01BB02: Prednisolone and mydriatics
— S01C: Antiinflammatory agents and antiinfectives in combination
— S01CA: Corticosteroids and antiinfectives in combination, opthalmologic
— S01CA02: Prednisolone and antiinfectives
— S01CB: Corticosteroids/antiinfectives/mydriatics in combination
— S01CB02: Prednisolone
— S02: Otologicals
— S02B: Corticosteroid otologicals
— S02BA: Corticosteroids
— S02BA03: Prednisolone
— S02C: Corticosteroids and antiinfectives in combination, otologic
— S02CA: Corticosteroids and antiinfectives in combination
— S02CA01: Prednisolone and antiinfectives
— S03: Ophthalmological and otological preparations
— S03B: Corticosteroid ophthalmologic and otologic preparations
— S03BA: Corticosteroids
— S03BA02: Prednisolone
— S03C: Corticosteroids and antiinfectives in combination, opthalmologic and otologic
— S03CA: Corticosteroids and antiinfectives in combination
— S03CA02: Prednisolone and antiinfectives
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AB: Antidotes
— V03AB05: Prednisolone and promethazine
HCPCS
No data
Clinical
Clinical Trials
2335 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 33 | 93 | 40 | 4 | 15 | 162 |
| Leukemia | D007938 | — | C95 | 16 | 68 | 21 | 7 | 9 | 107 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 11 | 47 | 24 | 9 | 6 | 85 |
| Prostatic neoplasms | D011471 | — | C61 | 12 | 33 | 27 | 5 | 10 | 79 |
| Syndrome | D013577 | — | — | 8 | 32 | 10 | 11 | 19 | 73 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 3 | 17 | 16 | 18 | 5 | 58 |
| Covid-19 | D000086382 | — | U07.1 | 3 | 9 | 24 | 7 | 17 | 56 |
| Kidney transplantation | D016030 | — | — | 5 | 19 | 14 | 20 | 3 | 56 |
| Inflammation | D007249 | MP_0001845 | — | 3 | 10 | 15 | 15 | 14 | 53 |
| Asthma | D001249 | EFO_0000270 | J45 | 2 | 9 | 10 | 16 | 16 | 52 |
Show 381 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | 18 | 39 | 16 | — | 7 | 71 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 15 | 47 | 14 | — | 2 | 67 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 12 | 40 | 15 | — | 5 | 64 |
| Myelodysplastic syndromes | D009190 | — | D46 | 10 | 39 | 2 | — | 4 | 49 |
| B-cell lymphoma | D016393 | — | — | 14 | 26 | 5 | — | 2 | 37 |
| Plasma cell neoplasms | D054219 | — | — | 9 | 16 | 6 | — | 6 | 37 |
| Preleukemia | D011289 | — | — | 4 | 22 | 2 | — | 3 | 27 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 5 | 19 | 3 | — | 1 | 26 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 10 | 18 | 2 | — | 1 | 24 |
| Alcoholic hepatitis | D006519 | EFO_1001345 | K70.1 | 1 | 6 | 9 | — | 7 | 22 |
Show 217 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloproliferative disorders | D009196 | — | D47.1 | 5 | 18 | — | — | 2 | 23 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | — | 1 | 11 | — | — | 2 | 14 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 3 | 9 | — | — | 1 | 12 |
| T-cell lymphoma | D016399 | — | — | 5 | 9 | — | — | — | 11 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 3 | 8 | — | — | 1 | 11 |
| Myeloid leukemia chronic-phase | D015466 | — | — | 2 | 8 | — | — | 1 | 10 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 3 | 7 | — | — | 1 | 10 |
| T-cell lymphoma peripheral | D016411 | — | — | 4 | 8 | — | — | — | 9 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 8 | — | — | — | 9 |
| Myeloid leukemia accelerated phase | D015465 | — | — | 2 | 6 | — | — | 1 | 8 |
Show 224 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pathologic dilatation | D004108 | — | — | 1 | — | — | — | 4 | 5 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | 1 | — | — | — | 3 | 4 |
| Intestinal diseases | D007410 | — | K63.9 | 1 | — | — | — | 2 | 3 |
| Therapeutic equivalency | D013810 | — | — | 3 | — | — | — | — | 3 |
| Precancerous conditions | D011230 | — | — | 2 | — | — | — | — | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | 1 | — | — | — | 1 | 2 |
| Friedreich ataxia | D005621 | Orphanet_95 | G11.11 | 2 | — | — | — | — | 2 |
| Retinal perforations | D012167 | EFO_1001028 | — | 1 | — | — | — | 1 | 2 |
| Fever | D005334 | — | R50.9 | 1 | — | — | — | 1 | 2 |
| Tinnitus | D014012 | — | H93.1 | 1 | — | — | — | 1 | 2 |
Show 26 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Morton neuroma | D000070607 | — | G57.6 | — | — | — | — | 3 | 3 |
| Rotator cuff injuries | D000070636 | — | M75.1 | — | — | — | — | 3 | 3 |
| Regeneration | D012038 | — | — | — | — | — | — | 3 | 3 |
| Uveomeningoencephalitic syndrome | D014607 | Orphanet_3437 | H20.82 | — | — | — | — | 3 | 3 |
| Mycoplasma infections | D009175 | — | — | — | — | — | — | 2 | 2 |
| Pleuropneumonia | D011001 | — | — | — | — | — | — | 2 | 2 |
| Keratoconjunctivitis | D007637 | — | H16.2 | — | — | — | — | 2 | 2 |
| Cicatrix | D002921 | — | L90.5 | — | — | — | — | 2 | 2 |
| Blood pressure | D001794 | EFO_0004325 | — | — | — | — | — | 2 | 2 |
| Vitiligo | D014820 | EFO_0004208 | L80 | — | — | — | — | 2 | 2 |
Show 173 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Prednisolone tebutate |
| INN | prednisolone |
| Description | Prednisolone tebutate is a corticosteroid hormone. |
| Classification | Small molecule |
| Drug class | steroids (not prednisolone derivatives); prednisone and prednisolone derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 7681-14-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200909 |
| ChEBI ID | 8381 |
| PubChem CID | 93055 |
| DrugBank | DB14632 |
| UNII ID | 9PHQ9Y1OLM (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 188 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
618 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use